Halper Sadeh LLC is Investigating Whether BOLD and NDRA are Obtaining Fair Deals for their Shareholders
Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.
GlobeNewsWire7/2/2026Neutral
NDRA
ENDRA Life Sciences IncNASDAQHEALTHCAREDIAGNOSTICS & RESEARCH
Key Statistics
Market Cap
$5.97M
P/E Ratio
—
EPS
$-8.16
Beta
-0.05
52W High
$9.85
52W Low
$2.96
50-Day MA
$5.03
200-Day MA
$4.93
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
0.00
About ENDRA Life Sciences Inc
ENDRA Life Sciences Inc. develops technology for clinical diagnostic ultrasound. The company is headquartered in Ann Arbor, Michigan.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-6.43M |
| Operating Margin | 0.00% |
| Return on Equity | -412.60% |
| Return on Assets | -122.30% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $1.44 |
| Price-to-Book | 3.35 |
| Price-to-Sales (TTM) | 1838.78 |
| EV/Revenue | 1845.91 |
| EV/EBITDA | -0.11 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $1.27M |
| Float | $1.20M |
| % Insiders | 8.73% |
| % Institutions | 9.66% |
Historical Volatility
HV 10-Day
239.68%
HV 20-Day
176.00%
HV 30-Day
152.53%
HV 60-Day
131.82%
HV Rank
—
Volatility is currently expanding
Analyst Ratings
Consensus ($25.00 target)
1
BuyLatest News
NDRA Stock Alert: Halper Sadeh LLC is Investigating Whether ENDRA Life Sciences Inc. is Obtaining a Fair Price for its Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the merger of ENDRA Life Sciences Inc. (NASDAQ: NDRA) with Noble Africa LLC. Upon closing of the proposed transaction, ENDRA shareholders are expected to own approximately 3% of the combined company.Halper Sadeh encourages ENDRA shareholders to click here to learn more about their rights and options or contact Daniel Sadeh or Zachary Halper free of charge at (212) 763-0060 or sadeh@halpersadeh.com or zhalp.
Business Wire6/25/2026Neutral
ENDRA Life Sciences Reports First Quarter 2026 Financial Results and Provides Business Update
ANN ARBOR, Mich.--(BUSINESS WIRE)---- $NDRA #MASLD--ENDRA Life Sciences Inc. (NASDAQ: NDRA) (“ENDRA” or the “Company”), a pioneer in thermoacoustic biomarker imaging for early detection and monitoring of steatotic liver disease (SLD), today reported financial results for the quarter ended March 31, 2026, and provided a business update. Business Update Initiated Evaluation of Strategic Alternatives On March 25, 2026, the Company announced that its Board of Directors has initiated a process to evaluate strategic.
Business Wire5/18/2026Neutral
ENDRA Life Sciences Reports Multi-Site Validation of TAEUS® Liver Device Demonstrating MRI-like Accuracy and Reproducibility
ANN ARBOR, Mich.--(BUSINESS WIRE)---- $NDRA #MASLD--ENDRA Life Sciences Inc. (NASDAQ: NDRA) (“ENDRA” or the “Company”), a pioneer in thermoacoustic biomarker imaging for the early detection and monitoring of steatotic liver disease (SLD), today announced multi-site clinical validation results for TAEUS® Liver that demonstrate strong concordance with MRI-PDFF, high reproducibility and consistent performance across clinical sites. The analysis combined data from 64 patients in the U.S. and Canada, including an ex.
Business Wire5/14/2026Neutral
More HEALTHCARE Stocks
Data last updated: 7/9/2026